Using engineered cells to treat arthritis through artificial signaling
Official title: Engineered cells as agents of arthritis therapy governed by artificial signaling
Funded at Vanderbilt University · NIH-10990815 · Data updated 2026-11-12
This study is exploring a new way to help people with osteoarthritis by creating special cells that can target and treat the damaged areas in their joints, aiming to reduce pain and help heal cartilage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | September 17, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $393,412 |
| NIH project number | 1R01AR083437-01A1 |
| Project ID | NIH-10990815 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with osteoarthritis who are experiencing joint degeneration and inflammation.
✕Less likely to help
Patients with osteoarthritis who are not experiencing significant joint degeneration or those with other unrelated conditions may not benefit from this research.
What this research studies
This research investigates a novel approach to treating osteoarthritis (OA) by engineering cells that can respond to specific signals in the joint environment. The goal is to create cells that can deliver therapeutic agents directly where they are needed, promoting cartilage regeneration and reducing inflammation. By utilizing advanced synthetic biology techniques, the project aims to develop a system that allows these cells to act as programmable agents, responding to the unique characteristics of joint degeneration. This could potentially lead to more effective treatments for patients suffering from OA.
Why it matters
Potential benefit: If successful, this research could provide a new, disease-modifying therapy for osteoarthritis, reducing the need for surgery and improving patient quality of life.
How similar studies have gone: While the approach of using engineered cells in regenerative medicine is gaining traction, this specific application in osteoarthritis treatment is relatively novel and has not been extensively tested.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Brunger, Jonathan Matthew — Vanderbilt University
- Study coordinator: Brunger, Jonathan Matthew
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Dose guide for physical activity to improve arthritis symptoms
A study from the University of South Carolina will look at how different amounts of weekly physical activity affect arthritis symptoms and quality of life in adults with arthritis.
-
Collaborating Center for Arthritis Care Tools and a Coordinating Center for an Arthritis Management & Wellbeing Network
A coordinated NIH program aims to improve how primary care providers refer people with arthritis to evidence-based, self-management programs and to boost participation, especially among groups facing disparities.
-
Arthritis prevention program to help adults with OA in mountain west communities
A program to help adults with osteoarthritis in the Mountain West connect with physical activity counseling and community activities to reduce activity limitations.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.